Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) and keeping the price target at $25.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors, primarily driven by Zevra Therapeutics’ strong financial performance and strategic initiatives. The company reported a significant increase in net revenue for the first quarter of 2025, surpassing both consensus and forecasted figures, largely due to the successful launch of Miplyffa. This new drug, approved in late 2024, has shown promising early adoption with substantial patient enrollment and a robust pricing strategy, indicating a potential for steep revenue growth.
Additionally, Zevra’s financial stability is reinforced by the sale of its priority review voucher, providing substantial non-dilutive funding. The company’s strategic focus on expanding Miplyffa’s market presence in Europe and its ongoing efforts in developing treatments for rare diseases further support the positive outlook. Despite some challenges with Olpruva’s slower-than-expected sales growth, the overall financial health and strategic direction of Zevra Therapeutics underpin McCarthy’s optimistic Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Medicus Pharma Ltd, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.7% and a 26.41% success rate on recommended stocks.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $19.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue